The world’s first inhaled Covid-19 vaccine was introduced at a press conference in Hainan, China on Wednesday.
The inhaled
vaccine was jointly developed by prominent Chinese
vaccine developer Chen Wei’s team and the Chinese biotech company, CanSino Biologics Inc..
The research team had earlier recruited 130 people to conduct the phase-1 clinical trials on the China-made inhaled
Covid vaccine, with its results published in an international medical journal - The Lancet.
The results show that the adverse side-effects in those who received the inhaled
vaccine were significantly lower than those receiving the injected
vaccines.
The researchers also said they are optimistic with this new type of
vaccine which they believe is better than traditional injectable shots in terms of efficiency and convenience.
The higher efficiency may come from the way the
vaccine enters the body, according to the researchers. It is directly inhaled through the nose, which mimics the natural infection of the respiratory virus
COVID-19, and then it forms a mucosal immunity.
“Such immunity was not made possible in traditional injectable
Covid jabs,” the researcher said.
Meanwhile, researchers told reporters that with the inhaled
vaccine dosage being only one-fifth that of the injectable
Covid vaccine, producers can make five times as many nasal spray
vaccines under the same production capacity for injectable
vaccines, which can contribute to speeding up vaccination in China.